Back to Search Start Over

Mouse liver repopulation with hepatocytes generated from human fibroblasts

Authors :
Milad Rezvani
Aras N. Mattis
Holger Willenbring
Saiyong Zhu
Sheng Ding
Leslie Z. Benet
Jack Harbell
Alan R. Wolfe
Source :
Nature. 508(7494)
Publication Year :
2013

Abstract

Human fibroblasts can be converted into hepatocytes capable of repopulating mouse livers by shortcutting reprogramming to pluripotency with factors promoting endoderm and hepatocyte differentiation. Previous studies have reported the production of liver cells from human embryonic and induced pluripotent stem (iPS) cells, but attempts to use them to repopulate liver tissue have been hampered by the failure of transplanted cells to proliferate. Holger Willenbring and colleagues adopted an alternative strategy for liver repopulation, converting human fibroblasts into mature hepatocytes capable of repopulating mouse livers. Their method bypasses an induced pluripotent state, instead reprogramming human fibroblasts to an induced multipotent progenitor cell (iMPC) state. From these cells the authors obtained endoderm progenitor cells (iMPC-EPCs) that generate surrogate hepatocytes capable of post-transplant maturation and proliferation. This work demonstrates the feasibility of significant liver repopulation of mice with human hepatocytes generated in vitro, establishing the system as a possible model for research on autologous therapy of human liver diseases. Human induced pluripotent stem cells (iPSCs) have the capability of revolutionizing research and therapy of liver diseases by providing a source of hepatocytes for autologous cell therapy and disease modelling. However, despite progress in advancing the differentiation of iPSCs into hepatocytes (iPSC-Heps) in vitro1,2,3, cells that replicate the ability of human primary adult hepatocytes (aHeps) to proliferate extensively in vivo have not been reported. This deficiency has hampered efforts to recreate human liver diseases in mice, and has cast doubt on the potential of iPSC-Heps for liver cell therapy. The reason is that extensive post-transplant expansion is needed to establish and sustain a therapeutically effective liver cell mass in patients, a lesson learned from clinical trials of aHep transplantation4. Here, as a solution to this problem, we report the generation of human fibroblast-derived hepatocytes that can repopulate mouse livers. Unlike current protocols for deriving hepatocytes from human fibroblasts, ours did not generate iPSCs but cut short reprogramming to pluripotency to generate an induced multipotent progenitor cell (iMPC) state from which endoderm progenitor cells and subsequently hepatocytes (iMPC-Heps) could be efficiently differentiated. For this purpose we identified small molecules that aided endoderm and hepatocyte differentiation without compromising proliferation. After transplantation into an immune-deficient mouse model of human liver failure, iMPC-Heps proliferated extensively and acquired levels of hepatocyte function similar to those of aHeps. Unfractionated iMPC-Heps did not form tumours, most probably because they never entered a pluripotent state. Our results establish the feasibility of significant liver repopulation of mice with human hepatocytes generated in vitro, which removes a long-standing roadblock on the path to autologous liver cell therapy.

Details

ISSN :
14764687
Volume :
508
Issue :
7494
Database :
OpenAIRE
Journal :
Nature
Accession number :
edsair.doi.dedup.....7505e3117dc7c945cc681039c0472d69